News

MinervaX raises upsized EUR 47.4M (USD 57M) Series B to advance its novel Group B Streptococcus vaccine through mid-stage clinical trials

Details

MinervaX, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), announced today that it has raised an upsized EUR 47.4 million Series B financing. 

Immatics Presents Phase I Data from ACTolog® Multi-Target Pilot Study IMA101 at the 35th Annual SITC Conference

Details

Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, announced today that the Company will present Phase I results from their ACTolog® program IMA101 at the 35th Annual SITC Meeting, held virtually from November 9-14, 2020. 

Koa Health secures over €14m initial funding and spins out of Telefónica’s moonshot factory

Details

The funding round led by Ancora Finance Group and Wellington Partners will bolster Koa Health’s growth ambitions to make mental health treatment more accessible with its wide range of digital solutions. 

  1. Digital therapeutics leader Sidekick raises $20M in Series A funding round led by Wellington and Asabys
  2. CARISMA Therapeutics announces FDA clearance of IND application for first-ever engineered macrophage immunotherapy
  3. Immatics announces completion of business combination and listing on NASDAQ
  4. SIRS Therapeutics: F4 Pharma’s FX06 shows promising results in critically ill COVID-19 patients
© Wellington Partners, 2021.